New [1,2,4]triazolo[4,3-c]quinazoline enhances cisplatin- and temozolomide-induced growth inhibition and apoptosis in HL-60 cells

The purpose of this study was to investigate the therapeutic potential of a newly synthesized [1,2,4]triazolo[4,3-c]quinazoline (NTCHMTQ) alone and in combination with two anticancer drugs (cisplatin and temozolomide) against HL-60 leukemia cell line. The IC50 value of NTCHMTQ toward HL-60 cells was...

Full description

Saved in:
Bibliographic Details
Published inNeoplasma Vol. 54; no. 1; p. 16
Main Authors Cipak, L, Letasiova, S, Repicky, A, Jantova, S
Format Journal Article
LanguageEnglish
Published Slovakia 2007
Subjects
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
Apoptosis - drug effects
Cell Cycle - drug effects
Cell Proliferation - drug effects
Cisplatin - pharmacology
Dacarbazine - analogs & derivatives
Dacarbazine - pharmacology
DNA Fragmentation - drug effects
Dose-Response Relationship, Drug
Drug Synergism
HL-60 Cells
Humans
Molecular Structure
Quinazolines - chemistry
Quinazolines - pharmacology
Triazoles - chemistry
Triazoles - pharmacology
Online AccessGet more information

Cover

More Information
Summary:The purpose of this study was to investigate the therapeutic potential of a newly synthesized [1,2,4]triazolo[4,3-c]quinazoline (NTCHMTQ) alone and in combination with two anticancer drugs (cisplatin and temozolomide) against HL-60 leukemia cell line. The IC50 value of NTCHMTQ toward HL-60 cells was 19.7 microM. No apoptosis and cell cycle changes were observed in cells treated with 5 microM NTCHMTQ alone. Combination of non-toxic concentrations of NTCHMTQ (1-5 microM) with cisplatin or temozolomide sensitized HL-60 cells to these two drugs and significantly enhanced their efficacies, that is illustrated by combination indexes, sub-G0 cell fraction, apoptotic DNA fragmentation and caspase-3 activity. The results suggest that combined therapy of non-toxic concentrations of NTCHMTQ with chemotherapeutics may provide synergistic regimen for treatment of leukemia. However, further in vitro and in vivo experimental drug-cell and drug-drug studies are warranted.
ISSN:0028-2685